Levine Leichtman Capital Partners, LLC’s Post

Avista Healthcare Partners VI Closes On $1.5 Billion📰 Avista Capital Partners has closed its 6th fund at $1.5bn, exceeding their $1.25bn. This fund aims to continue their successful strategy of value creation and growth in products and technology healthcare businesses. Fund 6 is their 3rd dedicated healthcare fund and will be invested across a number of sub-sectors including outsourced pharma, medical devices, and healthcare technology. • Avista Capital Partners has closed its 6th fund at $1.5bn, exceeding their $1.25bn. • This fund aims to continue their successful strategy of value creation and growth in products and technology healthcare businesses. • Fund 6 is their 3rd dedicated healthcare fund and will be invested across a number of sub-sectors including outsourced pharma, medical devices, and healthcare technology. https://lnkd.in/eB-zAxNE #privateequitynews #privatequity #rawselection

I guess the team Pacific Equity Partners are big fans of Dr Nick from the Simpsons or maybe it’s just defensible assets? In any event it would appear that they are having a good look at Integral Diagnostics (IDX) as part of their second Secure Assets Fund. Integral Diagnostics (IDX) has struggled recently with a market cap of $490m on $89m of EBITDA. Radiology clinics have been somewhat of a darling for private equity presenting defensible assets with high barriers of entry and stable cashflows. It would appear that Pacific Equity Partners team led by Andrew Charlier, Paul Foster and Evan Hattersley are keen to get their teeth stuck into the sector with a possible takeover offer for underperforming Integral Diagnostics (IDX) being a logical entry point. Pacific Equity Partners are arguable the leading private equity firm for public to private transactions having completed a number of them with great success including the most recent of Healthia Limited Australia. I would expect that a deal will be done quickly if the target ticks the boxes for the team at PEP. Certainly plenty of action at the moment in listed and unlisted markets! #privateequity #takeover #mergersandacquisitions #corporateadvisory

LevFin Insights reported on October 24, 2023 that Bausch Health is discussing potential lability management exercises with certain lenders under its Credit Agreement. Given this significant development, many subscribers have been asking about the implications of a hypothetical Asset Sale. Would such a sale, with all proceeds going towards the outstanding Credit Agreement, lead to the release of guarantees and collateral for the secured Bausch Health bonds? What about the guarantees for the unsecured Bausch Health bonds? In our latest report, we delve into these questions and provide comprehensive answers. Subscribers can read the full article here: https://hubs.li/Q02bdqbp0 #BauschHealth #Covenants

Here is the bottom line to CROs #iqvia #icon #parexel and all the remaining revenue FIRST and Service/Delivery Excellence LAST MINDED #CRO CROs are facing significant financial challenges due to the continued ABSENCE OF CRO EXECUTIVE LEADERSHIP's CLINICAL TRIAL KNOWLEGE. They need a clear strategy plan, a collaborative relationship mindset due to service and delivery failures, personnel retention plans, and proactive communication plans. Next time you are in a C-Level Executive Suite, ask the following questions: 1. Have you ever written a protocol? 2. Have you ever created CRFs and implemented a Data Validation Plan, Monitoring Plan, Audit Plan, or TMF Plan? 3. How do you define Data-Lock, and what are the steps to exceed client expectations to deliver the data ahead of schedule? 4. Have you been a PM, CTM, or PD? I recommend stopping at four questions because they have several excuses for why they are in the C-level position based on their executive leadership experience at XYZ fishing farm, which qualifies them for the role. The board members who govern these CROs must stop hiring regurgitated clowns who lead CROs into the ground. The #Fortrea CEO was warned of the above before he started his first day on the job.

Key insight: Attention self insured employers. If you are using a carrier and pbm that are non vertically integrated, you are paying more. More vetting process is needed during contract negotiations. #employeebenefits #verticalintegration #healthcare #pbm

I like the optimistic outlook! Question is: how far ahead is the US? 👀 — When can we expect some positive momentum to hit SMES in the Nordics? 📈 Sure would love to see some of that abundant large-pharma cash coming this way in 2024! 💰💰💰 (Not to mention the notion of a successful life science-IPO in Sweden again, that would be a sight for sore eyes!) 🥹 Interesting read from our friends at Back Bay Life Science Advisors nevertheless! 🤓 ”It will be interesting to see how deal making in the healthcare sector will perform in 2024. Potential interest rate cuts, large-pharma sitting on record high cash balances, approaching patent cliffs for blockbuster drugs, and the continuous growing list of companies in the IPO queue all provide reasons to be optimisitic.” #lifescience #nordics #momentum #ipo BioStock - Connecting Innovation and Capital

Join Andy Crawford's journey into pharmaceutical commercial investments, where strategic conversations with potential investors pave the path to success. Learn from Andy's approach to investor relations and unlock the key to fostering strong relationships in commercial real estate. 𝐓𝐡𝐢𝐧𝐠𝐬 𝐭𝐨 𝐥𝐞𝐚𝐫𝐧 𝐟𝐫𝐨𝐦 𝐭𝐡𝐢𝐬 𝐞𝐩𝐢𝐬𝐨𝐝𝐞: • Lessons you can learn from common mistakes in residential RE investing • The next step after buying your first property investment • Why you should attend the Invest Beyond Multifamily conference • Key questions to start conversations with potential pharmacy professional investors • How you can build trust with investors in the healthcare sector Subscribe so you don't miss out on great content, and if you love the show, leave an honest rating and review! Ep105 Cultivating Trust with Medical Professionals in CRE Syndications with Andy Crawford - Part 1 #StrategicInvesting #FinancialSuccess #InvestorNetworking Link in the comments.

SPAC Feed: Medical Properties Trust Responds to Latest WSJ Article – Business Wire - https://lnkd.in/e8u346bY Medical Properties Trust Responds to Latest WSJ Article  Business Wire Source: Medical Properties Trust Responds to Latest WSJ Article – Business… #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic

✍ Reporting live from SCOPE 2024 ✍ Team Medrio is in Orlando this week for #SCOPE and caught a great session from Validcare CEO, Patrick McCarthy, Esq. about how small biopharma organizations need to remain close to their trial data and look for partners who share the same goals and convictions. According to Patrick, it’s important for small biopharma to choose a partner based on a “realistic flight plan,” not just an RFP, and to demand one unified data platform, real-time visibility, and control from their partners. What has been your SCOPE highlight so far?

Hear Mr. Dheeresh Pathak, Fund Manager for the WhiteOak Capital Pharma and Healthcare Fund, as he discusses the trends and the fundamentals of the Healthcare Sector and it's attractiveness for investing. Watch the video here: https://lnkd.in/g4vSvTbf Invest in the WhiteOak Capital Pharma and Healthcare Fund - NFO now! Click here to invest: https://bit.ly/3NZq115 NFO period: 16th -30th Jan, 24